rs6265, BDNF;BDNF-AS

N. diseases: 272
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Our negative findings suggest that it is unlikely that the BDNF Val66Met polymorphism plays a major role in the pathogenesis of AD in the Chinese population and do not support previous findings that homozygosity for the 66Val allele confers an increased risk for AD. 14730194 2004
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Comparison of 487 Japanese AD subjects with 471 cognitively normal elderly controls showed higher frequencies of the G allele (60.5 vs. 55.5%, p = 0.028) and of both the GG and GA genotypes (85.8 vs. 79.8%, p = 0.025) of the G196A polymorphism in AD subjects than in controls and higher frequency of the T allele of the C270T polymorphism in AD subjects who were negative for apolipotrotein E4 (2.0 vs. 4.4%, p = 0.035) or positive for AD family history (2.8 vs. 7.1%, p = 0.046). 15375678 2005
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Association analysis of brain-derived neurotrophic factor (BDNF) gene 196 A/G polymorphism with Alzheimer's disease (AD) in mainland Chinese. 16054753 2005
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE We also tested BDNF Val66Met-C270T haplotypes for an interaction with the apolipoprotein E upsilon4 (APOE4) allele in AD. 16391475 2006
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE To study the role of BDNF 196 G>A and 270 C>T polymorphisms in Finnish AD and PD patients we genotyped BDNF 196 G>A and 270 C>T polymorphisms in 97 sporadic AD patients, 52 PD patients and 101 control subjects with polymerase chain reaction. 16565926 2006
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE These findings suggest that the functional BDNF Val66Met variant is not a major determinant of rate of cognitive decline in AD. 16627933 2006
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE This variant and two previously reported BDNF SNPs (C270T and Val66Met) were genotyped in 295 patients with AD, 108 with AFDs, 96 with posttraumatic stress disorder (PTSD), 84 with schizophrenia, 327 with alcohol and/or drug dependence, and 250 normal control subjects. 16649215 2006
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE To date, there have been several conflicting reports on the correlation between AD or PD and Val66Met or C270T polymorphism in the BDNF promoter region, although no data on this relationship have been published with respect to dementia with Lewy bodies (DLB). 16899999 2006
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Recently, several reports investigated the association between a single nucleotide polymorphism (Val66Met, rs6265) of the BDNF gene and AD but yielded ambiguous results. 17657167 2007
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. 18179845 2009
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Recent association studies have suggested that the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene could play a role in the development of AD. 18786162 2009
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE After stratification by sex, we found a significant allelic association between Val66Met and AD in women (P = 0.017), but not in men. 19504537 2010
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE A sample of AD subjects (N = 341) was genotyped for the BDNF polymorphisms: Val66Met, C270T, and G-712A. 19542613 2009
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease. 19812463 2010
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE A single nucleotide polymorphism in the human BDNF gene (Val66Met) affects memory, and influences Alzheimer's disease and depression vulnerability in a sex-specific manner. 20097294 2010
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Although Val66Met polymorphisms were not associated with the cross-sectional diagnoses of MCI or AD, the presence of Met-BDNF allele was associated with a higher risk of disease-progression in patients with MCI (OR=3.0 CI(95%) [1.2-7.8], P=0.02). 20491609 2010
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease. 20613678 2010
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE The gene variants of the BDNF Val66Met polymorphism were significantly associated with the presence of psychotic symptoms in male, but not in female patients with AD. 21044653 2011
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE To determine whether the BDNF Val66Met gene variant interacts with age to predict brain and cognitive measures in healthy volunteers across the adult lifespan in an intermediate phenotype pattern related to AD by examining (1) cortical thickness, (2) fractional anisotropy of white matter tracts (ie, white matter integrity), and (3) episodic memory performance. 21300947 2011
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE The current study examined potential association between single nucleotide polymorphisms (SNPs) of the BDNF gene (G11757 C, C270T, G196A, G-712A) and Alzheimer's disease-related depression (AD-D). 21677379 2011
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE One hundred and sixty-nine outpatients with AD or amnestic mild cognitive impairment (A-MCI) were recruited to the study and divided into three genotypic groups for each representative BDNF functional polymorphism as follows: (i) Val66Met (G196A): G/G (n = 45), G/A (n = 104), and A/A (n = 20); and (ii) C270T: C/C (n = 160), C/T (n = 9), and T/T (n = 0). 21951954 2011
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Among 200 outpatients with dementia and MCI, 146 outpatients with mild AD or A-MCI were recruited and divided into two genotypic groups, valine homozygosity (Val/Val) and methionine (Met) carriers, based on the representative BDNF functional polymorphism Val66Met. 22699449 2012
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE To investigate the possible relationship between genetic risk factors and depression in AD, we assessed genetic polymorphisms reported to be associated with depression (MAOA VNTR, ACE 288bp Insertion/ Deletion, 5HTTLPR, COMT Val158Met, BDNF Val66Met, TPH1 A218C, HTR2A T102C, P2RX7 Q460R, FKBP5 rs1360780 and CRHR1 rs242941) in a cross-sectional study on 246 AD patients with or without clinically significant major depressive disorder (MDD) according to DSM-IV. 23157339 2013
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE In conclusion, val66met polymorphism and BDNF serum level between the three groups and genotype did not significantly affect the serum BDNF level or age, Mini-Mental State Examination score in AD and aMCI. 23270505 2013
Alzheimer's Disease
CUI: C0002395
Disease: Alzheimer's Disease
0.100 GeneticVariation BEFREE Understanding the role of brain-derived neurotrophic factor (BDNF) in synaptic plasticity and synaptogenesis, the impact of the BDNF Val66Met polymorphism in Alzheimer's disease-relevant endophenotypes - including episodic memory and hippocampal volume - and the technological progress in measuring synaptic changes in humans all pave the way for a 'synaptic repair' therapy for neurodegenerative diseases that targets pathophysiology rather than pathogenesis. 23674053 2013